![](https://library.celltelligence.com/wp-content/uploads/2021/11/Autolus-Blackstone-featured.png)
$0
Why Blackstone’s $250M Investment in Autolus Is Necessary for Obe-cel’s Clinical Development
On Monday, November 8, Autolus announced (press release) that they have entered into a collaboration and financing agreement with Blackstone Life Sciences for the development of obe-cel (CD19 CAR-T, formerly AUTO1) and obe-cel’s next-generation therapies in B cell malignancies. Below, Celltelligence provides insights on how Autolus’s collaboration with Blackstone could secure obe-cel’s clinical development while giving the company flexibility to develop other assets within their pipeline.